No Data
No Data
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $254
BeiGene Canada Proud National Sponsor of the Leukemia & Lymphoma Society of Canada's 2024 Light The Night
TD Cowen Keeps Their Buy Rating on BeiGene (BGNE)
Express News | The Committee For Medicinal Products For Human Use Of The European Medicines Agency Issued Positive Opinions Recommending An Extended Authorization For BeiGene's Tevimbra (Tislelizumab) In Gastric Or Gastroesophageal Junction Adenocarcinoma And...
BeiGene Receives Positive CHMP Opinions for TEVIMBRA as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy